Literature DB >> 25969937

Spondylolysis and Beyond: Value of SPECT/CT in Evaluation of Low Back Pain in Children and Young Adults.

Andrew T Trout1, Susan E Sharp, Christopher G Anton, Michael J Gelfand, Charles T Mehlman.   

Abstract

Single photon emission computed tomography (SPECT)/computed tomography (CT) is ideally suited for assessment of low back pain in children and young adults. Spondylolysis is one of the most common structural causes of low back pain and is readily identified and characterized in terms of its chronicity and likelihood to heal. The value of SPECT/CT extends to identification and characterization of other causes of low back pain, including abnormalities of the posterior elements, developing vertebral endplate, transverse processes, and sacrum and sacroiliac joint. Some of the disease processes that are identifiable at SPECT/CT are similar to those that occur in adults (eg, facet hypertrophy) but may be accelerated in young patients by high-level athletic activities. Other processes (eg, limbus vertebrae) are more unique to children, related to injury of the developing spine. The authors review the spectrum of pars interarticularis abnormalities with emphasis on the imaging features of causes of pediatric low back pain other than spondylolysis. (©)RSNA, 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25969937     DOI: 10.1148/rg.2015140092

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  2 in total

1.  Primary pain generator identification by CT-SPECT in a patient with low back pain: a case report.

Authors:  Gabriel Tender; Adriana Constantinescu; Andrew Conger; Anthony DiGiorgio
Journal:  BMC Res Notes       Date:  2017-03-21

Review 2.  Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence.

Authors:  Ora Israel; O Pellet; L Biassoni; D De Palma; E Estrada-Lobato; G Gnanasegaran; T Kuwert; C la Fougère; G Mariani; S Massalha; D Paez; F Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-04       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.